Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Leveraging CRISPR-Cas for fast and accurate point-of-care diagnostics

Project description

Revolutionising point-of-care diagnostics

In critical healthcare scenarios such as sepsis and organ transplants, rapid and precise point-of-care diagnostics are indispensable for improving patient outcomes. Existing technologies often struggle to strike a balance between accuracy, speed, portability and cost-effectiveness. While immunoassays offer rapid results, they sacrifice accuracy, whereas PCR provides accuracy but at the expense of time and ease of use. Isothermal molecular tests, on the other hand, are swift but lack specificity. The EIC-funded SCOPE project aims to addresses this issue with scopeDx, a CRISPR-Cas diagnostic technology. Combining PCR’s precision with isothermal amplification’s speed, it delivers results in 30 minutes at the point of care. Developed by Scope Biosciences, this platform aims for user-friendliness, portability and cost-effectiveness. Its versatility extends to detecting various pathogens and genomic applications.

Objective

In the healthcare sector, rapid and precise point-of-care diagnostics is indispensable for enhancing patient outcomes, particularly in critical scenarios such as sepsis and organ transplantations. Present In Vitro Diagnostic technologies often strike a compromise between accuracy, speed, portability, and cost-effectiveness. Immunoassays offer rapidity but sacrifice accuracy, while molecular diagnostics like PCR deliver accuracy at the expense of time and ease of use. Isothermal molecular tests, on the other hand, are swift but lack specificity. Hence, a pressing need persists for point-of-care diagnostic tools that embody user-friendliness, cost-efficiency, high accuracy, and adaptability to diverse applications. At Scope Biosciences, a spin-off from Wageningen University, we have developed and patented a CRISPR-Cas diagnostic technology (scopeDx) that harnesses the precision of PCR and the speed of isothermal amplification, delivering rapid results within approximately 30 minutes at the point of care. Futhermore, the scopeDx platform can be rapidly adapted to new applications.
Our objective is to complete the pre-clinical validation of our solution to offer user-friendliness, robustness, portability, and cost-effectiveness, providing swift results directly at the point-of-care. Besides, we aim to prove the versatility of our platform, which can be extended to the detection of various pathogenic microbes (viruses, bacteria, fungi) and genomic applications (stem-cell & tissue transplantations).
In essence, scopeDx constitutes a modular platform technology with the potential to revolutionize the point-of-care diagnostics market comprehensively.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2023-TRANSITION-01

See all projects funded under this call

Coordinator

SCOPE BIOSCIENCES B.V.
Net EU contribution
€ 2 498 125,00
Address
BRONLAND 12 B 1
6708 WH Wageningen
Netherlands
SME
Yes
Region
Oost-Nederland Gelderland Veluwe
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 2 498 125,00